An official website of the United States government
Candidate malaria vaccine provides lasting protection in NIH-sponsored trials
- Candidate malaria vaccine provides lasting protection in NIH-sponsored trials
- Immunotherapy approach shows potential in some people with metastatic solid tumor
- Combination targeted treatment produces lasting remissions in people with resistant aggressive B-cell lymphoma
- NIH-funded clinical trial links frequent anger to increased risk of heart disease
- Hearing aids slow cognitive decline in people at high risk
- NIH clinical trial of tuberculous meningitis drug regimen begins
- Groundbreaking Trial Results Expand Treatment Options for Some People with Bladder Cancer
- Trial Confirms CAR T-Cell Therapy Benefits People with Aggressive Lymphomas
- Pragmatica-Lung Study, a streamlined model for future cancer clinical trials, begins enrolling patients
- NIH study finds that immunotherapy substantially increases survival of people with lymphomatoid granulomatosis
Approach could have role in preventing malaria in pregnancy.
NIH researchers achieved tumor shrinkage in three of seven patients with colorectal cancers.
Immunotherapy approach shows potential in some people with metastatic solid tumor
Combination therapy developed by NIH researchers demonstrates the power of precision medicine.
Findings demonstrate impairment of blood vessel function; may lead to heart attack, stroke.
NIH-funded clinical trial links frequent anger to increased risk of heart disease
Hearing aids cut the rate of cognitive decline by nearly half in older adults at high risk of dementia.
Hearing aids slow cognitive decline in people at high risk
Six-month multidrug regimen being evaluated against standard treatment.
NIH clinical trial of tuberculous meningitis drug regimen begins
For people with advanced bladder cancer, combining enfortumab (Padcev) and pembrolizumab (Keytruda) should be the new standard initial treatment, new clinical trial results suggest.
The CAR T-cell therapy axicabtagene ciloleucel (Yescarta) improved survival for people with large B-cell lymphoma that was not responding to initial treatment or had relapsed quickly, according to new data from the ZUMA-7 trial
NCI has helped launch the Pragmatica-Lung Study, a phase 3 randomized clinical trial of a two-drug combination to treat patients with advanced non-small cell lung cancer. The simplified trial design aims to increase accessibility for participants.
Patients treated with interferon alfa-2b lived for decades after diagnosis in Phase 2 trial.